Imaging to predict who benefits from chemoimmunotherapy before lung cancer surgery
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This study uses CT scan images to help doctors predict which patients with resectable lung cancer will benefit most from receiving chemoimmunotherapy (a combination of chemotherapy and immunotherapy) before surgery. The goal is to personalize treatment planning and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Confirmed diagnosis of non-small cell lung cancer (NSCLC) that can be surgically removed
- Cancer stage IIIA or lower
- Planning to receive chemoimmunotherapy before surgery as part of standard care
- Good overall health and ability to care for yourself (ECOG score 0 or 1)
- Able to understand and sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a treatment given before surgery for non-small cell lung cancer. Patients receive chemotherapy plus immunotherapy (chemo-immunotherapy) first, then have surgery to remove the tumor. The goal is to see how well this approach works.
This study looks at how well immunotherapy given before surgery works for non-small cell lung cancer. It aims to help doctors understand real-world outcomes for patients who receive this treatment.
This study tests whether giving a combination of chemotherapy and immunotherapy before surgery can improve outcomes for people with non-small cell lung cancer. Researchers are also studying how the bacteria in your gut (microbiome) affect how well the treatment works. This approach may shrink the tumor and make it easier to remove surgically.
This trial tests whether a special PET scan can predict how well your tumor responds to an immunotherapy drug given before surgery. Participation may help doctors tailor your treatment and improve outcomes for early-stage lung cancer.
This study tests a combination of an immunotherapy drug (sintilimab) and chemotherapy to see if it can shrink advanced lung cancer enough to make surgery possible. The goal is to improve outcomes for people whose cancer is currently too extensive for surgery.
This study is testing whether certain white blood cells (called neutrophils) in your tumor can predict how well a combination of chemotherapy and immunotherapy works before surgery for lung cancer. If you qualify, you would receive this treatment and then have surgery, and researchers would track your response.
Hear when a new Neoadjuvant Chemoimmunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.